WallStSmart

KNOREX LTD. (KNRX)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Zepp Health Corp generates 3077% more annual revenue ($258.90M vs $8.15M). ZEPP leads profitability with a -15.5% profit margin vs -92.8%. ZEPP earns a higher WallStSmart Score of 41/100 (D).

KNRX

Avoid

14

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 6.7Quality: 5.5
Piotroski: 6/9Altman Z: -15.42

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

KNRXUndervalued (+40.1%)

Margin of Safety

+40.1%

Fair Value

$1.47

Current Price

$1.07

$0.40 discount

UndervaluedFair: $1.47Overvalued
ZEPPUndervalued (+48.6%)

Margin of Safety

+48.6%

Fair Value

$46.70

Current Price

$17.47

$29.23 discount

UndervaluedFair: $46.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

KNRX1 strengths · Avg: 10.0/10
Debt/EquityHealth
-1.3310/10

Conservative balance sheet, low leverage

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

KNRX4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$38.03M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Revenue GrowthGrowth
-48.6%2/10

Revenue declined 48.6%

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : KNRX

The strongest argument for KNRX centers on Debt/Equity.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : KNRX

The primary concerns for KNRX are EPS Growth, Market Cap, Return on Equity.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

KNRX profiles as a turnaround stock while ZEPP is a hypergrowth play — different risk/reward profiles.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

Monitor SOFTWARE - APPLICATION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ZEPP scores higher overall (41/100 vs 14/100) and 43.0% revenue growth. KNRX offers better value entry with a 40.1% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

KNOREX LTD.

TECHNOLOGY · SOFTWARE - APPLICATION · USA

Knorex Ltd., a B2B technology company, specializes in providing programmatic advertising products and solutions to marketers to streamline and automate their advertising and marketing workflows. The company is headquartered in Singapore.

Visit Website →

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?